MetaCap

Mereo BioPharma Group (MREO) vs OS Therapies (OSTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OS Therapies (OSTX) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 53.0% versus a loss of 85.6%. OS Therapies is the larger company by market cap ($42.0 million vs $41.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MREO-85.56%OSTX-53.04%
+37%-28%-93%
Nov 21, 20251 yearNov 20, 2026
MREO-93.28%OSTX-79.92%
+35%-32%-100%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MREO versus OSTX key metrics
MetricMREOOSTX
Share price$0.26$0.803
Market cap$41.52M$42.00M
1-day change-5.45%-2.12%
YTD return-37.65%-42.64%
1-year return-85.56%-53.04%
5-year return-86.32%—
Forward P/E—2.29
EPS (TTM)$-0.15$-1.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$500.00K—
Net income (latest FY)$-41.88M$-28.75M
Operating margin-8021.40%—
Net margin-8375.60%—
52-week high$2.37$2.25
52-week low$0.20$0.58
Distance from 52-week high-89.03%-64.31%
Analyst consensusnonestrong_buy
Avg. price target upside+653.85%+958.53%
Average volume1.24M722.66K
Shares outstanding159.70M52.30M
Employees394
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OSTX has outperformed MREO by 32.5 percentage points over the past year.

About Mereo BioPharma Group

MREO stock →

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

MREO vs OSTX FAQ

Which is bigger, Mereo BioPharma Group or OS Therapies?

OS Therapies (OSTX) is larger, with a market capitalization of $42.00M compared with $41.52M for Mereo BioPharma Group (MREO).

Which stock has performed better over the past year, MREO or OSTX?

OSTX returned -53.04% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.

Are Mereo BioPharma Group and OS Therapies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons